Entrepreneurial Support Program(Explore Course)
- Principal Investigator
-
Tokyo University of Science
Motoshi Hayano
- Adopted Theme
Development of a novel small compound for sarcopenia treatment induced by GLP-1 receptor agonists (GLP-1 RAs)
- Subject of Research
- Development of a novel small compound for sarcopenia treatment induced by GLP-1 receptor agonists (GLP-1 RAs)
- Overview
-
We aims to develop a therapeutic drug for sarcopenia, a condition associated with decreased muscle mass and strength, which leads to frailty and increased mortality risk. Specifically, we are focusing on developing small-molecule compounds targeting sarcopenia induced by GLP-1 receptor agonists (GLP-1 RAs), which have gained attention as anti-obesity drugs and are projected to reach a market size of approximately 23 trillion yen by 2030. While competing companies have focused on monoclonal antibody drugs targeting Activin receptors for muscle hypertrophy, previous clinical trials have failed to improve muscle function. Our drug candidates have demonstrated superiority in non-clinical studies in terms of efficacy, cost, and patient adherence, particularly in improving muscle quality and strength. In the future, this drug is expected to contribute to improving patients' quality of life (QOL) in a wide range of muscle-related diseases, including age-related sarcopenia, cancer cachexia, and rare muscular disorders.
- Business Models（when applying）
This project is designed with the goal of acquisition by a major pharmaceutical company. Specifically, we plan to present non-clinical and clinical efficacy and safety data of our small-molecule compounds to global companies involved in the development and commercialization of GLP-1 RAs. Currently, many pharmaceutical companies are working to develop longer-lasting and more effective oral GLP-1 RAs. By addressing the limitations of existing GLP-1 RAs through a novel molecular mechanism distinct from competitors, our project aims to deliver significant value to the industry.
- Activity Planning（when applying）
In this project, we aim to identify key business development challenges, including market dynamics, technology advancements, organizational structure, and intellectual property strategy. Our goal is to develop a business plan that enhances corporate value from an investor’s perspective while fostering collaboration opportunities with pharmaceutical companies. Throughout the project, we will engage in discussions with international corporations and investors. Additionally, we plan to strengthen our team by recruiting members with expertise in corporate negotiations and clinical development. In our research and development efforts, we are advancing two drug pipelines: one that enhances the weight loss effects of GLP-1 RAs and another that prevents GLP-1 RA-induced sarcopenia. Currently, we are moving towards the development stage of lead compounds. During the project, we plan to obtain activity-relationship data and subsequently file a substance patent. As we refine our patent and development strategies and prepare for global negotiations, we will proceed with the establishment of our startup.